Evidence map›Paper›PMID 25984572›Full record

ArticleACS biomaterials science & engineering2015

Design strategies and applications of circulating cell-mediated drug delivery systems.

Yixue Su, Zhiwei Xie, Gloria B Kim, Cheng Dong, Jian Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS biomaterials science & engineering, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Cell-drug conjugates.Nature biomedical engineering · 2024
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yixue Su *Department of Biomedical Engineering, Materials Research Institutes, the Huck Institutes of Life Sciences, The Pennsylvania State University, W340 Millennium Science Complex, University Park, PA 16802.
Zhiwei Xie *Department of Biomedical Engineering, Materials Research Institutes, the Huck Institutes of Life Sciences, The Pennsylvania State University, W340 Millennium Science Complex, University Park, PA 16802.
Gloria B KimDepartment of Biomedical Engineering, Materials Research Institutes, the Huck Institutes of Life Sciences, The Pennsylvania State University, W340 Millennium Science Complex, University Park, PA 16802.
Cheng DongDepartment of Biomedical Engineering, Materials Research Institutes, the Huck Institutes of Life Sciences, The Pennsylvania State University, W340 Millennium Science Complex, University Park, PA 16802.
Jian YangDepartment of Biomedical Engineering, Materials Research Institutes, the Huck Institutes of Life Sciences, The Pennsylvania State University, W340 Millennium Science Complex, University Park, PA 16802.

Funding

Developing targeted therapy with prostate cancer specific nanomedicineR01CA182670 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HSIEH, JER-TSONG, YANG, JIAN · 2013 to 2017
$1.6M
Novel Engineered Particle Platform for Endothelium RegenerationR01HL118498 · NHLBI · UNIVERSITY OF TEXAS ARLINGTON · PI NGUYEN, KYTAI TRUONG, YANG, JIAN · 2014 to 2017
$1.5M
Creating Safe Biodegradable Photoluminescent Implant PolymersR01EB012575 · NIBIB · UNIVERSITY OF TEXAS ARLINGTON · PI YANG, JIAN · 2011 to 2014
$1.2M
NCI NIH HHS R01 CA182670NHLBI NIH HHS R01 HL118498NIBIB NIH HHS R01 EB012575
6 · The paper itself

Abstract

Drug delivery systems, particularly nanomaterial-based drug delivery systems, possess a tremendous amount of potential to improve diagnostic and therapeutic effects of drugs. Controlled drug delivery targeted to a specific disease is designed to significantly improve the pharmaceutical effects of drugs and reduce their side effects. Unfortunately, only a few targeted drug delivery systems can achieve high targeting efficiency after intravenous injection, even with the development of numerous surface markers and targeting modalities. Thus, alternative drug and nanomedicine targeting approaches are desired. Circulating cells, such as erythrocytes, leukocytes, and stem cells, present innate disease sensing and homing properties. Hence, using living cells as drug delivery carriers has gained increasing interest in recent years. This review highlights the recent advances in the design of cell-mediated drug delivery systems and targeting mechanisms. The approaches of drug encapsulation/conjugation to cell-carriers, cell-mediated targeting mechanisms, and the methods of controlled drug release are elaborated here. Cell-based "live" targeting and delivery could be used to facilitate a more specific, robust, and smart payload distribution for the next-generation drug delivery systems.

Indexed as

circulating cellsdrug deliveryimmune cellsnanoparticlesstem cellstargeting

Identifiers

PMID25984572
PMCPMC4428174

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.